Jupiter Topco LLC Purchases Shares of 17,965,847 Vaxcyte, Inc. $PCVX

Jupiter Topco LLC purchased a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 17,965,847 shares of the company’s stock, valued at approximately $1,044,355,000. Jupiter Topco LLC owned 12.07% of Vaxcyte as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of PCVX. Janus Henderson Group PLC boosted its holdings in Vaxcyte by 23.8% during the first quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock valued at $960,231,000 after purchasing an additional 3,188,687 shares in the last quarter. BlackRock Inc. acquired a new position in Vaxcyte during the second quarter worth $701,520,000. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Vaxcyte by 35.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 11,296,333 shares of the company’s stock valued at $521,213,000 after acquiring an additional 2,981,038 shares during the period. Wellington Management Group LLP boosted its stake in shares of Vaxcyte by 18.5% in the 4th quarter. Wellington Management Group LLP now owns 5,966,310 shares of the company’s stock valued at $275,286,000 after purchasing an additional 933,539 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of Vaxcyte by 4.1% in the 4th quarter. State Street Corp now owns 4,980,005 shares of the company’s stock valued at $229,777,000 after purchasing an additional 194,116 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on PCVX. Wall Street Zen upgraded Vaxcyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Zacks Research upgraded shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Vaxcyte has a consensus rating of “Moderate Buy” and a consensus target price of $86.00.

Insiders Place Their Bets

In other Vaxcyte news, CFO Andrew Guggenhime sold 10,000 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $53.89, for a total value of $538,900.00. Following the completion of the transaction, the chief financial officer owned 105,176 shares of the company’s stock, valued at $5,667,934.64. This represents a 8.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $53.86, for a total transaction of $121,185.00. Following the sale, the chief operating officer directly owned 157,541 shares in the company, valued at $8,485,158.26. The trade was a 1.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 120,646 shares of company stock valued at $6,570,810. 3.30% of the stock is owned by corporate insiders.

Vaxcyte Price Performance

Shares of NASDAQ PCVX opened at $61.09 on Wednesday. The business has a 50-day moving average of $56.91 and a 200-day moving average of $55.88. The stock has a market capitalization of $9.09 billion, a price-to-earnings ratio of -8.01 and a beta of 1.23. Vaxcyte, Inc. has a fifty-two week low of $29.87 and a fifty-two week high of $65.00.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same period last year, the company posted ($1.22) EPS. On average, sell-side analysts expect that Vaxcyte, Inc. will post -7.6 EPS for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.